AR054838A1 - Compuestos inhibidores del virus de la hepatitis c - Google Patents

Compuestos inhibidores del virus de la hepatitis c

Info

Publication number
AR054838A1
AR054838A1 ARP060103034A ARP060103034A AR054838A1 AR 054838 A1 AR054838 A1 AR 054838A1 AR P060103034 A ARP060103034 A AR P060103034A AR P060103034 A ARP060103034 A AR P060103034A AR 054838 A1 AR054838 A1 AR 054838A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
och2p
alkynyl
alkenyl
Prior art date
Application number
ARP060103034A
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR054838A1 publication Critical patent/AR054838A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a compuesto inhibidores de VHC, composiciones que contienen dichos compuestos, y métodos terapéuticos que incluyen la administracion de dichos compuestos, como también a los procesos e intermediarios utiles para preparar dichos compuestos. Reivindicacion 1: Un compuesto, incluyendo los enantiomeros del anterior, de formulas (1), (2), (3) o (4), o una sal, o un solvato de los anteriores aceptables desde el punto de vista farmacéutico, donde: R1 es selecciona de manera independiente de H, alquilo, alquenilo, alquinilo, arilo, cicloalquilo, heterociclo, halogeno, haloalquilo, alquilsulfonamido, arilsulfonamido, -C(O)NHS(O)2-, o -S(O)2-, sustituidos de manera opcional con uno o más A3; R2 se selecciona de: a) - C(Y1)(A3); b) alquilo C2-10, cicloalquilo C3-7 o alquiloCl-4-cicloalquiloC3-7, donde dicho cicloalquilo y alquil-cicloalquilo puede ser mono-, di- o tri-sustituido con alquilo C1-3; o donde dicho alquilo, cicloalquilo y alquil-cicloalquilo pueden ser mono- o di-sustituidos con sustituyentes seleccionados de hidroxi y O-alquiloC1-4; o donde cada uno de dichos grupos alquilo puede ser mono-, di- o tri-sustituido con halogeno; o donde cada uno siendo de dichos grupos cicloalquilo es de 5, 6, o 7 miembros, uno o dos grupos -CH2- que no están unidos directamente entre sí pueden reemplazarse por -O- de manera tal que el átomo de O esté unido al átomo de N al cual R2 está unido a través de por lo menos dos átomos de C; o c) fenilo, alquilC1-3- fenilo, heteroarilo o alquilC1-3-heteroarilo, donde los grupos heteroarilo son de 5 o 6 miembros y tienen desde 1 hasta 3 heteroátomos seleccionados de N, O y S, donde dichos grupos fenilo y heteroarilo pueden estar mono-, di- o tri-sustituidos con sustituyentes seleccionados de halogeno, -OH, alquilo C1-4, O-alquiloCl-4, S-alquiloCl-4, -NH2, -NHalquiloCl-4 y -N(alquiloCl-4)2, -CONH2 y -CONH-alquiloCl-4; R3 es PRT, H o alquilo Cl-6; L se selecciona de manera independiente de C o N, siempre que no haya mas de tres N consecutivos, cada uno sustituido de manera opcional con uno o más A3; Z es O, S, C o N; sustituido en forma opcional con A3; Z2a es H, alquilo Cl-l0, alquenilo C2-10, alquinilo C2-10, donde cualquier átomo de carbono puede ser reemplazado con un heteroátomo seleccionado de O, S o N, o Z2a manera opcional forma un carbociclo o heterociclo con Q1 o cualquier A3; Z2b es H, alquilo Cl-6, alquenilo C2-8, alquinilo C2-8; Q1 es alquilo Cl, alquenilo C2-8, o alquinilo C2-8; A3 se selecciona de manera independiente de PRT, H, -OH, -C(O)OH, -(CH2)m-, -C(O)O-, - NH-, ciano, alquilo, alquenilo, alquinilo, amino, amido, imido, imino, halogeno, CF3, CH2CF3, cicloalquilo, nitro, arilo, aralquilo, alcoxi, ariloxi, heterociclo, heteroarilo, -C(A2)3, -C(A2)2-C(O)A2, -C(O)A2, -C(O)OA2, -O(A2), -N(A2)2, -S(A2), -CH2P(O)(A2)(OA2), -CH2P(O)(A2)(N(A2)2), -CH2P(O)(OA2)(OA2), -OCH2P(O)(OA2)(OA2), -OCH2P(O)(A2)(OA2), -OCH2P(O)(A2)(N(A2)2), -C(O)OCH2P(O)(OA2)(OA2), - C(O)OCH2P(O)(A2)(OA2), -C(O)OCH2P(O)(A2)(N(A2)2), -CH2P(O)(OA2)(N(A2)2), -OCH2P(O)(OA2)(N(A2)2), -C(O)OCH2P(O)(OA2)(N(A2)2), -CH2P(O)(N(A2)2)(N(A2)2), -C(O)OCH2P(O)(N(A2)2)(N(A2)2), -OCH2P(O)(N(A2)2)(N(A2)2), -(CH2)m-heterociclo, - (CH2)mC(O)Oalquilo, -O-(CH2)m-O-C(O)-Oalquilo, -O-(CH2)r-O-C(O)-(CH2)m-alquilo, -(CH2)mO-C(O)-O-alquilo, -(CH2)mO-C(O)-O-cicloalquilo, -N(H)C(Me)C(O)O-alquilo, o alcoxi arilsulfonamida; donde cada A3 puede estar sustituido en forma opcional con 1 hasta 4-R1, -P(O)(OA2)(OA2), -P(O)(OA2)(N(A2)2), -P(O)(A2)(OA2), -P(O)(A2)(N(A2)2) o -P(O)(N(A2)2)(N(A2)2), halogeno, alquilo, alquenilo, alquinilo, arilo, carbociclo, heterociclo, aralquilo, arilsulfonamida, arilalquilsulfonamida, ariloxi sulfonamida, ariloxi, alquilsulfonamida, ariloxi arilsulfonamida, alquilsulfonamida, alquiloxi sulfonamida,, alquiloxi alquilsulfonamida, -(CH2)m-heterociclo, -(CH2)m-C(O)O-alquilo, -O(CH2)mOC(O)Oalquilo, -O-(CH2)m-O-C(O)-(CH2)m-alquilo, -(CH2)m-O- C(O)-O-alquilo, -(CH2)m-O-C(O)-O-cicloalquilo, -N(H)C(CH3)C(O)O-alquilo, alcoxi, -N(R3)(R3) o alcoxi arilsulfonamida, sustituida en forma opcional con -R1; o A3 forma un anillo carbocíclico o heterocíclico con cualquier otro A3 o Q1; Y1 es O, S, N(R2), N(OR2) o N(N(R2)2; A2 se selecciona de manera independiente de H, alquilo, alquenilo, alquinilo, amino, aminoácido, alcoxi, ariloxi, ciano, haloalquilo, cicloalquilo, arilo, heteroarilo, alquilsulfonamida, o arilsulfonamida, sustituida en forma opcional con A3; m es 0 a 6; r es 1 hasta 2; y q es hasta 10.
ARP060103034A 2005-07-14 2006-07-14 Compuestos inhibidores del virus de la hepatitis c AR054838A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69909605P 2005-07-14 2005-07-14
US70055905P 2005-07-18 2005-07-18

Publications (1)

Publication Number Publication Date
AR054838A1 true AR054838A1 (es) 2007-07-18

Family

ID=37387254

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103034A AR054838A1 (es) 2005-07-14 2006-07-14 Compuestos inhibidores del virus de la hepatitis c

Country Status (13)

Country Link
US (1) US20070072809A1 (es)
EP (1) EP1907403B1 (es)
JP (1) JP2009501724A (es)
KR (1) KR101345008B1 (es)
CN (1) CN101243096B (es)
AR (1) AR054838A1 (es)
AU (1) AU2006267066A1 (es)
BR (1) BRPI0613056A2 (es)
CA (1) CA2614276A1 (es)
MX (1) MX2008000609A (es)
NZ (1) NZ564830A (es)
TW (1) TWI389908B (es)
WO (1) WO2007009109A2 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003007697A (ja) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc 半導体装置の製造方法、基板処理方法および基板処理装置
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
EP2305697A3 (en) * 2005-07-25 2011-07-27 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
NZ568135A (en) 2005-10-11 2011-06-30 Array Biopharma Inc Macrocyclic compounds and methods for inhibiting hepatitis C viral replication
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7906619B2 (en) 2006-07-13 2011-03-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
CA2663159A1 (en) * 2006-09-13 2008-03-20 Novartis Ag Organic compounds and their uses
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2677843A1 (en) * 2007-02-20 2008-08-28 Novartis Ag Macrocyclic compounds as hcv ns3 protease inhibitors
AP2009005053A0 (en) * 2007-05-03 2009-12-31 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
KR20100027134A (ko) 2007-05-10 2010-03-10 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 펩티드 억제제
AR067442A1 (es) 2007-06-29 2009-10-14 Gilead Sciences Inc Compuestos antivirales
WO2009005690A2 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
WO2009005677A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
NZ586232A (en) 2007-12-21 2012-12-21 Avila Therapeutics Inc HCV protease inhibitors comprising a functionalised proline derivative
AU2008340257B2 (en) 2007-12-21 2015-06-11 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8309685B2 (en) * 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
WO2009099596A2 (en) 2008-02-04 2009-08-13 Idenix Pharamaceuticals, Inc. Macrocyclic serine protease inhibitors
CA2719008A1 (en) 2008-03-20 2009-09-24 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis c virus inhibitors
AU2009249443A1 (en) * 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis C virus replication
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009148923A1 (en) 2008-05-29 2009-12-10 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2009324643B2 (en) 2008-12-10 2014-08-28 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2010080389A1 (en) * 2008-12-19 2010-07-15 Gilead Sciences, Inc. Hcv ns3 protease inhibitors
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
CA2758072A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
KR20130026410A (en) * 2009-09-28 2013-03-13 Intermune Inc Cyclic peptide inhibitors of hepatitis c virus replication
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
WO2011075615A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EA201390988A1 (ru) 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9115175B2 (en) 2013-03-14 2015-08-25 Achillion Pharmaceuticals, Inc. Processes for Producing sovaprevir
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
BR112015023351A2 (pt) 2013-03-15 2017-07-18 Achillion Pharmaceuticals Inc forma cristalina de sovaprevir, composição farmacêutica, e, método para tratar um distúrbio
US9006423B2 (en) 2013-03-15 2015-04-14 Achillion Pharmaceuticals Inc. Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CN107427529A (zh) 2014-12-26 2017-12-01 埃莫里大学 N4‑羟基胞苷和衍生物及与其相关的抗病毒用途
SG11201809893WA (en) 2016-05-27 2018-12-28 Gilead Sciences Inc Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
DE69129650T2 (de) * 1990-09-14 1999-03-25 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Wirkstoffvorläufer von Phosphonaten
US6018049A (en) * 1996-12-26 2000-01-25 Shionogi & Co., Ltd. Process for the preparation of carbamoylated imidazole derivatives
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6457524B1 (en) * 2000-09-15 2002-10-01 Halliburton Energy Services, Inc. Well cementing compositions and methods
AU2002248147B2 (en) * 2000-11-20 2006-04-06 Bristol-Myers Squibb Company Hepatitis C tripeptide inhibitors
YU52303A (sh) * 2001-01-31 2006-05-25 Warner-Lambert Company Postupak karbamoilacije alkohola
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US7091184B2 (en) * 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2370396A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6642204B2 (en) * 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
PL211889B1 (pl) * 2002-05-20 2012-07-31 Bristol Myers Squibb Co Pochodna heterocyklosulfonamidowa, kompozycja ją zawierająca oraz ich zastosowanie
ATE413411T1 (de) * 2002-05-20 2008-11-15 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
US7132504B2 (en) * 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) * 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) * 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7705146B2 (en) * 2004-06-28 2010-04-27 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor peptide analogs
MX2007000584A (es) * 2004-07-16 2007-06-25 Gilead Sciences Inc Compuestos antivirales.

Also Published As

Publication number Publication date
TWI389908B (zh) 2013-03-21
MX2008000609A (es) 2008-03-19
US20070072809A1 (en) 2007-03-29
EP1907403B1 (en) 2013-12-25
WO2007009109A3 (en) 2007-06-07
AU2006267066A1 (en) 2007-01-18
BRPI0613056A2 (pt) 2010-12-14
CA2614276A1 (en) 2007-01-18
TW200738741A (en) 2007-10-16
NZ564830A (en) 2010-12-24
CN101243096B (zh) 2013-02-06
WO2007009109A2 (en) 2007-01-18
CN101243096A (zh) 2008-08-13
KR20080027947A (ko) 2008-03-28
KR101345008B1 (ko) 2013-12-31
EP1907403A2 (en) 2008-04-09
JP2009501724A (ja) 2009-01-22

Similar Documents

Publication Publication Date Title
AR054838A1 (es) Compuestos inhibidores del virus de la hepatitis c
AR054837A1 (es) Compuestos inhibidores del virus de la hepatitis c
AR050174A1 (es) Derivados de fosfonatos con actividad antiviral. composiciones farmaceuticas
AR061840A1 (es) Compuestos fosfinatos antivirales
AR068794A1 (es) Compuestos antivirales
AR067180A1 (es) Compuestos antivirales
PE20090042A1 (es) Analogos de ciclopamina
AR053153A1 (es) Derivados de pirazina -2- carboxamida como antagonistas de mglur5
AR059512A1 (es) Derivados de piridina -2- carboxamida
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR060405A1 (es) Compuestos organicos y sus usos en tratamientos de infeccion por el virus de hepatitis c
AR054232A1 (es) Derivados de piridina -2- carboxamida como antagonistas de mglur5
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
AR078944A1 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
AR081831A1 (es) Inhibidores de la proteina ns5a del virus de la hepatitis c (vhc)
AR061629A1 (es) Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas
AR048241A1 (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c .
AR044152A1 (es) Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
AR039554A1 (es) Compuestos derivados de aminopirimidina y aminopiridina, su empleo, un metodo para su preparacion, composiciones que los comprenden, y compuestos intermediarios
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
PE20091096A1 (es) Compuestos organicos
AR052549A1 (es) Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2
AR067646A1 (es) Ariloxazoles sustituidos y su uso
AR080263A1 (es) Inhibidores ns5a de vhc
AR083161A1 (es) Inhibidores macrociclicos de la replicacion del virus de la hepatitis c, composiciones farmaceuticas que los comprenden, su uso en medicamentos, intermediarios de su sintesis y metodos de preparacion de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FA Abandonment or withdrawal